New hope for kidney cancer: Real-World study tests vorolanib as Second-Line therapy
NCT ID NCT06676527
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well the drug vorolanib works for people with advanced kidney cancer that cannot be removed by surgery or has spread. It is for patients who need a second treatment after their first one stopped working. The study will track how long the cancer stays under control and any side effects, using real-world data from about 39 participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTINEOPLASTIC AGENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jinling Hospital
RECRUITINGNanjing, Jiangsu, 401520, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple screening program could transform cancer aftercare
- A new program aims to ease the 'Lost in Transition' struggle for cancer survivors
- A tiny dose of an old drug might stop Post-Surgery brain fog in seniors
- Could a phone app help parents of kids with special needs thrive?
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Can a new immune drug outsmart Hard-to-Treat tumors?